Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 14/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | KIF5B | P33176 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24409213 | 0.92 | RET (0.55) | RETJAK2KIF5BKDRFLT3 | |
| SCHEMBL30728233 | 0.92 | RET (0.55) | RETJAK2KIF5BKDRFLT3 | |
| SCHEMBL24409347 | 0.90 | RET (0.48) | RETJAK2KIF5BKDRFLT3 | |
| SCHEMBL24409121 | 0.86 | RET (0.51) | RETJAK2KIF5BKDRFLT3 | |
| SCHEMBL30630854 | 0.86 | RET (0.51) | RETJAK2KIF5BKDRFLT3 | |
| SCHEMBL24409142 | 0.86 | RET (0.56) | RET | |
| SCHEMBL24409193 | 0.85 | RET (0.56) | RET | |
| SCHEMBL24409306 | 0.85 | RET (0.41) | RETJAK2 | |
| SCHEMBL29972723 | 0.84 | RET (0.48) | RETJAK2KIF5BKDRFLT3 | |
| SCHEMBL24409106 | 0.84 | RET (0.54) | RETJAK2KIF5BKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | ELLIPSES PHARMA LTD (GB) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOTUM, FURIN, CYP4A11 | RET 8/4885JAK2 1317/4885KIF5B 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.